ABT vs INCY: fair value comparison
Abbott Laboratories and Incyte Corporation · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, INCY currently sits closer to the top of our discount ranking. INCY carries the stronger quality grade.
| ABT | INCY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $108.33 | $126.75 |
| 12-month range | $87.78–$128.01 | $93.48–$125.01 |
| Sector rank | #40 of 113 Healthcare | #37 of 113 Healthcare |
| Quality grade | B | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: ABT fair value analysis · INCY fair value analysis